Who are the top shareholders of the Genomic Valley?

The top shareholders of Genomic Valley are Yogesh Agrawal with 46.72%, and Deepti Aggarwal, the largest public shareholder, with 11%. Individual investors collectively own 52.62% of the shares, with no institutional holdings or pledged promoter shares reported.

The top shareholders of Genomic Valley include Yogesh Agrawal, who holds the largest stake at 46.72%. The highest public shareholder is Deepti Aggarwal, with a holding of 11%. Additionally, individual investors collectively hold 52.62% of the company's shares. There are no institutional holdings or pledged promoter shares reported.

Has Genomic Valley declared dividend?

No Dividend History Available

Who are the peers of the Genomic Valley?

Genomic Valley's peers include Sun Pharma, Divi's Lab, Cipla, and Dr Reddy's Labs, among others. Divi's Lab leads with a 1-year return of 51.96%, while Genomic Valley's return is 29.73%, higher than Decipher Labs' -37.27%.

Peers: The peers of Genomic Valley are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Venmax Drugs, Decipher Labs, Span Divergent, Unjha Formul., and Checkpoint Trend.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Average management risk is found at Decipher Labs and Unjha Formul. Good growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Divi's Lab., Torrent Pharma, Decipher Labs, and Unjha Formul., and the rest. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma and Unjha Formul., and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Decipher Labs has the lowest at -37.27%. Genomic Valley's 1-year return of 29.73% is higher than that of Decipher Labs but lower than Divi's Lab. Additionally, several peers, including Decipher Labs, Span Divergent, and Unjha Formul., have negative six-month returns.

What is the technical trend for Genomic Valley?

As of May 26, 2025, Genomic Valley's technical trend has shifted to bearish, supported by bearish signals from the MACD, KST, and moving averages, while the RSI indicates a lack of momentum.

As of 26 May 2025, the technical trend for Genomic Valley has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly MACD and KST both signaling bearish momentum. The daily moving averages also confirm a bearish trend. The Bollinger Bands and Dow Theory indicate a mildly bearish outlook on the weekly and monthly time frames. The RSI shows no signal, suggesting a lack of momentum in either direction. Overall, the technical indicators collectively point towards a bearish sentiment in the market for Genomic Valley.

Who are in the management team of Genomic Valley?

As of March 2022, the management team of Genomic Valley includes Yogesh Agrawal (Chairman & Managing Director), Parul Agrawal (Director), Gupta Pradeep (Independent Director), Jyoti Bansal (Additional Director), and Praveen Kumar Mishra (Additional Director). Only Yogesh Agrawal has specified remuneration of 5.5 lacs INR.

As of March 2022, the management team of Genomic Valley includes the following individuals:<BR><BR>1. Yogesh Agrawal - Chairman & Managing Director<BR>2. Parul Agrawal - Director<BR>3. Gupta Pradeep - Independent Director<BR>4. Jyoti Bansal - Additional Director<BR>5. Praveen Kumar Mishra - Additional Director<BR><BR>Yogesh Agrawal is the only member with a specified remuneration, which is 5.5 lacs INR. The other directors do not have remuneration listed.

What does Genomic Valley do?

Genomic Valley Biotech Ltd is a micro-cap company focused on biotechnology research and the commercial production of plant tissue cultured plants. As of March 2025, it reported net sales of 3 Cr and a net loss of 1 Cr, with a market cap of INR 15 Cr.

Overview: <BR>Genomic Valley Biotech Ltd is a micro-cap company in the Pharmaceuticals & Biotechnology industry, focused on conducting research in biotechnology and commercial production of plant tissue cultured plants.<BR><BR>History: <BR>Incorporated in May 1994, Genomic Valley Biotech Ltd has been engaged in its objectives since its inception. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 3 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 15 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>Industry P/E: 32 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.00 <BR>Return on Equity: 0.00% <BR>Price to Book: 0.00 <BR><BR>Contact Details: <BR>Address: 4 KM Stone Berry Chhara Road, Tehsil Bahadurgarh jhajjar Haryana : 124507 <BR>Tel: 91-9811341542 <BR>Email: genomicvalley@gmail.com <BR>Website: http://www.genomicvalley.com

How big is Genomic Valley?

As of 24th July, Genomic Valley Biotech Ltd has a market capitalization of 15.00 Cr, with net sales of 0.85 Cr and a net profit of 0.36 Cr reported in the latest four quarters. The balance sheet for March 2024 shows shareholder's funds of 3.54 Cr and total assets of 4.33 Cr.

As of 24th July, Genomic Valley Biotech Ltd has a market capitalization of 15.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Genomic Valley reported Net Sales of 0.85 Cr and a Net Profit of 0.36 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 3.54 Cr and Total Assets of 4.33 Cr.

Why is Genomic Valley falling/rising?

As of N/A, Genomic Valley Biotech Ltd is priced at 40.90, with a recent slight increase but significant declines over various periods, including a 48.23% year-to-date decrease. The stock has underperformed compared to the Sensex, which has seen a minor decline, indicating company-specific challenges.

As of N/A, Genomic Valley Biotech Ltd is currently priced at 40.90, reflecting a slight increase of 0.02 or 0.05%. However, the stock has experienced significant declines over various periods, with a 1-week drop of 21.32%, a 1-month decline of 15.50%, and a year-to-date decrease of 48.23%. The stock's performance over the past year shows a decline of 32.40%, while it has outperformed the benchmark Sensex over the 3-year period with a return of 19.77%. Unfortunately, the "Today's Price Summary" and the "Positive and Negative Factors" sections are not available, which limits the analysis of immediate influences on the stock's movement.<BR><BR>In the broader market context, Genomic Valley's recent performance contrasts sharply with the Sensex, which has only seen a minor decline of 0.03% over the past week. The stock's substantial short-term losses highlight a significant underperformance compared to the benchmark, particularly over the last month and year-to-date. While the Sensex has shown a positive return of 3.15% year-to-date, Genomic Valley's drastic decline suggests company-specific challenges that are not reflected in the broader market trends.

When is the next results date for Genomic Valley?

The next results date for Genomic Valley is 15 October 2025.

The next results date for Genomic Valley is scheduled for 15 October 2025.

How has been the historical performance of Genomic Valley?

Genomic Valley's historical performance has shown significant fluctuations, with net sales peaking at 2.72 Cr in Mar'23 before declining to 0.84 Cr in Mar'25, although profitability improved with a profit after tax of 0.36 Cr in Mar'25. The company faces ongoing challenges, as total liabilities and assets have decreased, and cash flow from operations remains stagnant.

Answer:<BR>The historical performance of Genomic Valley shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Genomic Valley's net sales have varied considerably, peaking at 2.72 Cr in Mar'23 before dropping to 0.84 Cr in Mar'25. The total operating income followed a similar trend, with a high of 2.72 Cr in Mar'23 and a decrease to 0.84 Cr in Mar'25. The company experienced an operating profit (PBDIT) of 0.43 Cr in Mar'25, a recovery from a loss of -0.30 Cr in Mar'22, indicating improved operational efficiency. Profit before tax also showed a positive trend, reaching 0.44 Cr in Mar'25, while profit after tax was 0.36 Cr in the same period, up from a loss of -0.01 Cr in Mar'22. The operating profit margin improved significantly to 51.19% in Mar'25, reflecting better cost management. Total liabilities decreased to 4.33 Cr in Mar'24 from 7.61 Cr in Mar'21, and total assets also declined to 4.33 Cr in Mar'24. The company's cash flow from operating activities remained stagnant, with no cash inflow recorded in recent years. Overall, while Genomic Valley has shown some recovery in profitability, its sales and asset levels indicate ongoing challenges.

Which are the latest news on Genomic Valley?